Compare Ishares Msci Spain ETF (EWP) vs Incyte Corporation (INCY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Spain ETF vs Incyte Corporation — how do they compare? Ishares Msci Spain ETF trades at $59.23, while Incyte Corporation trades at $115 (market cap $22.99B). Which is the better fit depends on your goals.
| EWP | INCY | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $60.28 | $118.52 |
52-Week Low | $43.90 | $67.38 |
Market Cap | — | $22.99B |
Enterprise Value | — | $19.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWP trades at $59.26, showing minimal daily movement with a 0.02% gain. Technical indicators signal a bullish trend, supported by strong moving average alignment, while oscillators remain neutral. The stock exhibits tight support at $59 and resistance at $60. A dividend of $0.92 per share is scheduled for payment on June 18, 2026.
The outlook for EWP is cautiously optimistic due to bullish technicals and upcoming dividend returns. Key risks include European economic sensitivity to energy price volatility and potential interest rate impacts. Investors should monitor ECB policy decisions and regional economic performance for directional cues.
INCY trades at $115.83, up 0.83% today, with a bullish technical signal from moving averages and strong fundamental performance including 2025 revenue of $5.14B and net income of $1.29B. Recent developments include positive Phase 1/2 data for VGA039 presented at ISTH 2026 and the acquisition of Vega Therapeutics, expanding its hematology portfolio. The stock shows robust profitability with a 26.71% net income margin and 30.82% ROE, while analyst consensus is a Buy with a $112.78 price target.
Outlook remains positive driven by pipeline advancements and earnings growth, though risks include clinical trial outcomes and regulatory hurdles. The current price above the consensus target suggests limited near-term upside, but continued execution could support further gains. Investors should weigh strong cash flow generation against competitive pressures in the biopharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Spain ETF
EWP is a country-specific ETF that tracks the performance of the Spanish equity market. It provides targeted access to large and mid-sized companies in Spain, with heavy weightings in financials and utilities like Banco Santander and Iberdrola.
Read more on EWP →About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →
